Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

nced the reduction in tumor volume produced by cyclophosphamide and cisplatin. There was a 130 percent, 65 percent and 70 percent decrease in the tumor volume of animals administered with SPI (IRL)-1620 plus cyclophosphamide as compared to cyclophosphamide alone on day 10, 16 and 22, respectively. Similarly, the reduction in tumor volume in SPI (IRL)-1620 plus cisplatin treated animals was 31 percent, 68 percent and 80 percent greater on day 10, 16 and 22, respectively compared to cisplatin alone treated animals.

Conclusion

In conclusion, SPI (IRL)-1620 significantly enhanced the efficacy of cyclophosphamide and cisplatin in a preclinical model of ovarian tumor in mice.

About EOquin

EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the inner most lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study for which patient accrual was completed this year, EOquin instilled into the bladder following TUR-BT was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, would carry a low risk of harming the rest of the body.

Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced 67% CRs (complete responses) in patients, many of whom had been treated multiple times. EOquin received a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for non-invasive bladder cancer and the Company expects to begin enrollment of the first patients in the Phase 3 trial this quarter.

About Satraplatin

Satraplatin, a fourth-generation, oral investigational drug, is a member of the plati
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
(Date:12/14/2009)... CARROLLTON, Ga., Dec. 14 /PRNewswire/ ... that its flagship integrated EHR, Prime Suite ... conditionally CCHIT Certified(®) 2011 Ambulatory EHR, additionally ... with optional Advanced Reporting. Greenway,s Prime Suite ... two new 2011 certification designations offered by ...
(Date:12/14/2009)... Therapeutics (NYSE Amex: CXM ) announced a ... in the Treatment of Diabetic Ulcers," at the ... held December 10-13, 2009 in St. Thomas, U.S. ... top industry leaders and renowned researchers in the ... K. Sosnowski, Cardium,s Vice President of Biologics Development ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 3Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 4Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4554 000 in Massachusetts Struggle to Put Food on the Table 61847 1554 000 in Massachusetts Struggle to Put Food on the Table 61847 2554 000 in Massachusetts Struggle to Put Food on the Table 61847 3554 000 in Massachusetts Struggle to Put Food on the Table 61847 4Congressional Health Care Reform Proposals Would Make Health Care More Expensive Reduce Benefits for Louisianians 61843 1Congressional Health Care Reform Proposals Would Make Health Care More Expensive Reduce Benefits for Louisianians 61843 2Heritage Provider Network CEO Dr Richard Merkin Announces the Acquisition of Lakeside Medical Systems Inc 61839 1Heritage Provider Network CEO Dr Richard Merkin Announces the Acquisition of Lakeside Medical Systems Inc 61839 2Heritage Provider Network CEO Dr Richard Merkin Announces the Acquisition of Lakeside Medical Systems Inc 61839 3
... efficacy and safety of once-daily TMC278 in ... treatment-naive adults with ... phase IIb data from Tibotec,Pharmaceuticals Ltd. provides additional information ... investigational,non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of HIV,combination ...
... Interferon-Beta-CTP Development Program Has Been Approved For, First Year Funding Through ... ... Chief Scientist -, NES-ZIONA, Israel, Aug. 5 ... subsidiary,has received approval for a special grant from the Israeli Office ...
Other Medicine Technology:Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 2Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 3Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 4
(Date:12/15/2009)... in the Dec. 15 issue of the Journal ... or obese increases the risk for developing obstructive sleep ... , Results indicate that the risk of ... older increased 3.5 fold with each standard-deviation increase in ... OSA did not significantly increase with increasing BMI among ...
(Date:12/14/2009)... BROOK, Ill., Dec. 15 In today,s ... larger role than ever. Now the University HealthSystem ... resources, Value Analysis: Achieving Cost Efficiencies in ... in these complex environments. These new materials, developed ... the field, provide a practical guide to planning, ...
(Date:12/14/2009)... PARK, Ill. and HOLLYWOOD, Fla., Dec. 14 ... ) announced today a definitive agreement to ... ), a leading provider of laboratory information ... cash. ,, The acquisition strengthens Abbott,s ... providing advanced web-based applications to help laboratories ...
(Date:12/14/2009)... Dec. 14 Aflac Incorporated announced today ... of thirty-year senior notes with a coupon of ... price of 98.951 to yield 6.984%. The company ... debt repayment and general corporate purposes. ,, Commenting ... Incorporated President and Chief Financial Officer Kriss Cloninger ...
(Date:12/14/2009)... in one gene, researchers say , , MONDAY, Dec. 14 ... genetic variants in a single gene linked to heart ... Medicine in St. Louis analyzed the DNA of a ... identified 129 variants in four genes that could be ... with heart failure and 625 healthy whites led the ...
Breaking Medicine News(10 mins):Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4
... The Executives, a support group of nearly 500 prominent ... funds for the Los Angeles Jewish Home, presented its ... the group,s president, and the Jack Schlaifer Visionary Award ... awards lunch and installation event.The Tom Bane Humanitarian Award ...
... the "standard of care" for patients with complex coronary ... New England Journal of Medicine (online February ... study, led jointly by Patrick Serruys from Erasmus University ... the University of Leipzig (Germany), set out to compare ...
... Indicates Improper Revenue Accounting Related to Two Transactions , ... a world leader in stabilized rice bran (SRB) nutrient ... preliminary findings and recommendations of the Audit Committee of ... statements for the fiscal year ended December 31, 2007. ...
... Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the ... it will be exhibiting at the upcoming Chicago Dental ... of its highly successful sales of the STA ... year,s CDS conference, coupled with four successive quarters of ...
... DataMentors(R), the industry leading full-service data quality ... release of its much anticipated DataFuse(TM) version 5.0. ... platforms. DataFuse is used by a diverse cross-section ... companies, providing the industry,s highest level of data ...
... a new chapter of your life can be a scary ... graduating from college, getting married, having your first child, or ... overwhelmed with how this change affects the rest of your ... a Difference" ( published by AuthorHouse ) by Robert C.K. ...
Other Medicine News:Health News:Los Angeles Jewish Home Support Group Presents Humanitarian Award and Visionary Award 2Health News:Los Angeles Jewish Home Support Group Presents Humanitarian Award and Visionary Award 3Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 2Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 3Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 2Health News:NutraCea to Restate Financial Statements for 2007 and 2008 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 5Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 3Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 4Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:'Standing on the Edge of Tomorrow: You Can Make a Difference' 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: